Date: 2014-05-13
Type of information: Clinical research agreement
Compound: Viaskin® Milk
Company: DBV Technologies (France) Children’s Hospital of Philadelphia (USA - PA)
Therapeutic area: Allergic diseases - Inflammatory diseases - Digestive diseases
Type agreement: clinical research
Action mechanism: Viaskin® Milk is a ready-to-use and easy-to-administer form of allergen immunotherapy, particularly adapted to the pediatric population. Viaskin® Milk is intended to induce clinical desensitization / tolerization to milk in subjects moderately to severely allergic to cow’ milk proteins. Specific immunotherapy of CMA might decrease the risk of relapse and might be the first treatment of EoE. Moreover, by utilizing the epicutaneous route of administration, Viaskin® Milk is able to initiate an immunomodulatory process while minimizing the potential safety concerns associated with systemic exposure to food allergens.
Disease: milk-induced eosinophilic esophagitis
Details: * On May 13, 2014, DBV Technologies announced signing a clinical agreement with Dr. Jonathan Spergel at The Children’s Hospital of Philadelphia to conduct a clinical trial on the development of Viaskin® Milk in milk-induced eosinophilic esophagitis (EoE). A double-blind, placebo-controlled, randomized trial will study efficacy and safety of the Viaskin® Milk epicutaneous immunotherapy in treating milk induced Eosinophilic Esophagitis in children ages from 4 to 17 years old (SMILEE study). Under the terms of the agreement, SMILEE will be conducted at The Children\'s Hospital of Philadelphia under the supervision of Dr. Spergel.
Financial terms:
Latest news:
